Serina Therapeutics Inc.
SER | AMEX
$2.33
+$0.02 (+0.87%)
Sep 22, 2026, 12:32 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 56K | 3.15M | 500K | 3.46M | 54K |
Cost of Revenue | n/a | 194K | 90K | n/a | 3.8M | 1.28M |
Gross Profit | n/a | -138K | 3.06M | 500K | -333.84K | -1.23M |
Operating Income | -24.02M | -17.05M | -3.13M | -2.27M | -1.63M | -10.41M |
Interest Income | n/a | n/a | n/a | 1.76K | 10.86K | n/a |
Pretax Income | -19.2M | -11.21M | 5.27M | -2.68M | -1.26M | -10.4M |
Net Income | -19.18M | -11.14M | 5.27M | -2.68M | -1.26M | -10.87M |
Selling & General & Admin | 11M | 9.43M | 3.89M | 1.29M | 1.3M | 5.6M |
Research & Development | 13.16M | 7.48M | 2.39M | 1.57M | 3.8M | 3.58M |
Other Expenses | -130K | n/a | -90K | -91.5K | -3.8M | n/a |
Operating Expenses | 24.02M | 16.91M | 6.19M | 2.77M | 1.3M | 9.18M |
Interest Expense | 213K | 526K | 558K | 15.88K | 3.09K | 404K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 24.02M | 17.1M | 6.28M | 2.77M | 5.1M | 10.46M |
Income Tax Expense | 18K | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 10.19M | 7.36M | 8.41M | 1.08M | 1.08M | 1.07M |
Shares Outstanding (Diluted) | 10.19M | 7.36M | 8.41M | 1.08M | 1.08M | 1.07M |
EPS (Basic) | -1.91 | -1.51 | 0.63 | -2.49 | -0.59 | -10.14 |
EPS (Diluted) | -1.91 | -1.51 | 0.63 | -2.49 | -0.59 | -10.14 |
EBITDA | -18.91M | -10.49M | 5.92M | -2.6M | -1.23M | -8.74M |
EBIT | -18.98M | -10.68M | 5.83M | -2.67M | -1.26M | -10M |
Depreciation & Amortization | 73K | 194K | 90K | 61.27K | 33.37K | 1.26M |
Add to Watchlist
Select watchlists to add or remove SER